A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

PlanetDrugsDirect.com has been providing quality medications to satisfied American patients at heavily discounted prices for over twenty years.

Pfizer CEO Albert Bourla told investors he dined with RFK Jr, a vaccine skeptic and nominee to head HHS. They discussed ...

Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis.

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying "kickbacks" ...

Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...